DocGo Inc. (DCGO) Guidance & Earnings Results

On 2026-08-17 DocGo Inc. lowered guidance: "FY2026 adjusted EBITDA guidance cut from -$5 to -$10M to -$17 to -$22M; revenue guidance narrowed to $305-310M from…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

DCGODocGo Inc.Follow DCGO — free

Medical Care Facilities · Healthcare

—

Price chart with a free account

Market cap: 26.8M
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 9 Nov, in 16 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
17 Aug 26	Lowered	FY2026 adjusted EBITDA guidance cut from -$5 to -$10M to -$17 to -$22M; revenue guidance narrowed to $305-310M from $300-315M · full year
11 May 26	Raised	Revenue guidance raised to $300-$315M from $290-$310M (midpoint +$7.5M) · full year
16 Mar 26	Raised	2026 revenue and adjusted EBITDA guidance raised due to customer expansions, improved EMS hiring rates and efficiency initiatives · full year
10 Nov 25	Mixed	FY25 revenue $315-320M (prior $300-330M); FY25 adjusted EBITDA loss $25-28M (prior loss $20-30M); FY26 revenue $280-300M; FY26 adjusted EBITDA loss $15-25M. · full year
7 Aug 25	Reaffirmed	FY2025 revenue $300-330M; adjusted EBITDA loss $20-30M · full year

DocGo Inc. — questions

What guidance did DocGo Inc. give?: On 2026-08-17: "FY2026 adjusted EBITDA guidance cut from -$5 to -$10M to -$17 to -$22M; revenue guidance narrowed to $305-310M from $300-315M"
When does DocGo Inc. report earnings?: DocGo Inc.'s next earnings report is expected on 2026-11-09.

Every figure on this page comes from DocGo Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.